Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16096116 | 0.85 | BACE1 (0.46) | HSD17B10BACE1CLCN2MAPTMAOB | |
| SCHEMBL2220583 | 0.81 | RORC (0.54) | HSD17B10MAPTTDP1TSHRCYP1A2 | |
| SCHEMBL10709145 | 0.80 | HSD17B10 (0.50) | HSD17B10S1PR4MAPTTDP1TTR | |
| SCHEMBL6099115 | 0.79 | MAOB (0.53) | BACE1MAPTMAOBTSHRCYP3A4 | |
| SCHEMBL12587297 | 0.79 | BACE1 (0.43) | BACE1MAPTMAOB | |
| SCHEMBL12800776 | 0.79 | MAPT (0.53) | S1PR4MAPTTDP1MRGPRX4CYP1A2 | |
| SCHEMBL17658992 | 0.79 | MRGPRX4 (0.40) | BACE1CLCN2S1PR4ENPP2MAPT | |
| SCHEMBL2096187 | 0.78 | MAOB (0.56) | HSD17B10BACE1MAPTTTRMAOB | |
| SCHEMBL2768003 | 0.78 | CYP3A4 (0.44) | S1PR4MAPTMRGPRX4TSHRCYP3A4 | |
| SCHEMBL15969116 | 0.78 | HPGD (0.54) | S1PR4TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010127208-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-04 | — | — | WO | disclosed |
| US-7022732-B2 | 6-substituted 2,3-dihydro-1,4-benzodioxine, 2-position substituted with carboxy, or (C1 C6)alkoxycarbonyl; diabetes, obesity; 6-[2-(R)-[2-(S)-hydroxy-3-(4-hydroxy-3-methanesulfonamido-phenoxy)propylamino]propyl]-2,3-dihydro-1,4-benzodioxine-2-(R)-carboxylic acid; B3 andrenergic receptor agonist | NISSHIN PHARMA INC. (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040235921-A1 | Propanolamine derivative having 1, 4-Benzodioxane ring | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1426370-A1 | PROPANOLAMINE DERIVATIVE HAVING 1,4 BENZODIOXANE RING | Nisshin Pharma Inc. (JP) | 2004-06-09 | — | — | EP | disclosed |
| EP-0321984-B1 | MESOMORPHIC COMPOUND HAVING BETA-HYDROXYCARBOXYL GROUP AS CHIRAL SOURCE AND LIQUID CRYSTAL COMPOSITION | MITSUBISHI RAYON CO., LTD. (JP) | 1992-10-21 | — | — | EP | disclosed |
| US-4925591-A | FERROELECTRIC | MITSUBISHI RAYON CO., LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
| EP-0321984-A1 | Mesomorphic compound having beta-hydroxycarboxyl group as chiral source and liquid crystal composition | MITSUBISHI RAYON CO., LTD. (JP) | 1989-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235921-A1 | Propanolamine derivative having 1, 4-Benzodioxane ring | ADRA1D, ADRA1A, ADRB1 | HSD17B10 201/4885BACE1 2566/4885CLCN2 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.